Allogenic CD123-CAR-NK Cells therapy(JD Biotech)

N/A

Report date: 2022/11/09 20:01:39

Base Information

Drug NameAllogenic CD123-CAR-NK Cells therapy(JD Biotech)
Drug Alias NameJD023
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionInterleukin-3 receptor subunit alpha inhibitors
TargetsInterleukin-3 receptor subunit alpha
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesChinese Academy Of Military Medical SciencesBeijing JD Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing JD Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A